Details:
Under the agreement, BMS has obtained LianBio’s exclusive rights for Camzyos (mavacamten), the first and only cardiac myosin inhibitor approved, in Mainland China and Asia for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy.
Lead Product(s): Mavacamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Camzyos
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 24, 2023
Details:
SINTBILO (tafolecimab) is an lgG2 fully human monoclonal antibody that can specifically bind to PCSK9, which being investigated for the treatment of patients with primary hypercholesterolemia and mixed dyslipidemia.
Lead Product(s): Tafolecimab
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Sintbilo
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023
Details:
Camzyos (mavacamten), a cardiac myosin inhibitor, recently got approved in Macau for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Lead Product(s): Mavacamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Camzyos
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
Camzyos (mavacamten) is a cardiac myosin inhibitor, got recently approved in Macau fot the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Lead Product(s): Mavacamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Camzyos
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
The proceeds will fund the future acquisitions and business development of five cardiovascular and metabolic products, including Ebrantil®, Edarbi®, Blopress®, Basen®, and Actos®. Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker, used to treat hypertension.
Lead Product(s): Azilsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Edarbi
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: CBC Group
Deal Size: $315.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 20, 2023
Details:
The announcement showed that Lisinopril Tablets are mainly used for the treatment of essential hypertension (EH) and renal vascular hypertension (RVH) and were originally researched and developed by Astrazeneca and approved for launch in the United States in 1988.
Lead Product(s): Lisinopril
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2020